|
1
|
Russell PJ and Kingsley EA: Human prostate
cancer cell lines. Methods Mol Med. 81:21–39. 2003.PubMed/NCBI
|
|
2
|
Whang PG, Gamradt SC, Gates JJ and
Lieberman JR: Effects of the proteasome inhibitor bortezomib on
osteolytic human prostate cancer cell metastases. Prostate Cancer
Prostatic Dis. 8:327–334. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Potosky AL, Miller BA, Albertsen PC and
Kramer BS: The role of increasing detection in the rising incidence
of prostate cancer. JAMA. 273:548–552. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanks GE, Krall JM, Hanlon AL, Asbell SO,
Pilepich MV and Owen JB: Patterns of Care and RTOG studies in
prostate cancer: Long-term survival, hazard rate observations, and
possibilities of cure. Int J Radiat Oncol Biol Phys. 28:39–45.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zincke H, Oesterling JE, Blute ML,
Bergstralh EJ, Myers RP and Barrett DM: Long-term (15 years)
results after radical prostatectomy for clinically localized (stage
T2c or lower) prostate cancer. J Urol. 152:1850–1857.
1994.PubMed/NCBI
|
|
6
|
Crawford ED, Eisenberger MA, McLeod DG,
Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA and
Goodman PJ: A controlled trial of leuprolide with and without
flutamide in prostatic carcinoma. N Engl J Med. 321:419–424. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eisenberger MA, Crawford ED, Wolf M,
Blumenstein B, McLeod DG, Benson R, Dorr FA, Benson M and Spaulding
JT: Prognostic factors in stage D2 prostate cancer; important
implications for future trials: Results of a cooperative intergroup
study (INT.0036). The National Cancer Institute Intergroup Study
#0036. Semin Oncol. 21:613–619. 1994.PubMed/NCBI
|
|
8
|
Newling DW, Denis L and Vermeylen K:
Orchiectomy versus goserelin and flutamide in the treatment of
newly diagnosed metastatic prostate cancer. Analysis of the
criteria of evaluation used in the European Organization for
Research and Treatment of Cancer - Genitourinary Group Study 30853.
Cancer. 72(Suppl 12): 3793–3798. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bracarda S, Logothetis C, Sternberg CN and
Oudard S: Current and emerging treatment modalities for metastatic
castration- resistant prostate cancer. BJU Int. 107(Suppl 2):
13–20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sartor O, Halstead M and Katz L: Improving
outcomes with recent advances in chemotherapy for
castrate-resistant prostate cancer. Clin Genitourin Cancer.
8:23–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Papandreou CN and Logothetis CJ:
Bortezomib as a potential treatment for prostate cancer. Cancer
Res. 64:5036–5043. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yerlikaya A and Yöntem M: The significance
of ubiquitin proteasome pathway in cancer development. Recent
Patents Anticancer Drug Discov. 8:298–309. 2013. View Article : Google Scholar
|
|
13
|
Yerlikaya A and Erin N: Differential
sensitivity of breast cancer and melanoma cells to proteasome
inhibitor Velcade. Int J Mol Med. 22:817–823. 2008.PubMed/NCBI
|
|
14
|
Yerlikaya A, Okur E and Ulukaya E: The
p53-independent induction of apoptosis in breast cancer cells in
response to proteasome inhibitor bortezomib. Tumour Biol.
33:1385–1392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Freshney RI: Cytotoxicity. Culture of
Animal Cells: A Manual of Basic Technique (5th). John Wiley and
Sons Inc. (Hoboken, NJ). 3592005.
|
|
16
|
Pham LV, Tamayo AT, Li C, Bornmann W,
Priebe W and Ford RJ: Degrasyn potentiates the antitumor effects of
bortezomib in mantle cell lymphoma cells in vitro and in vivo:
Therapeutic implications. Mol Cancer Ther. 9:2026–2036. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adams J, Palombella VJ, Sausville EA,
Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and
Elliott PJ: Proteasome inhibitors: A novel class of potent and
effective antitumor agents. Cancer Res. 59:2615–2622.
1999.PubMed/NCBI
|
|
18
|
Kiliccioglu I, Konac E, Varol N, Gurocak S
and Bilen Yucel C: Apoptotic effects of proteasome and histone
deacetylase inhibitors in prostate cancer cell lines. Genet Mol
Res. 13:3721–3731. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Williams S, Pettaway C, Song R, Papandreou
C, Logothetis C and McConkey DJ: Differential effects of the
proteasome inhibitor bortezomib on apoptosis and angiogenesis in
human prostate tumor xenografts. Mol Cancer Ther. 2:835–843.
2003.PubMed/NCBI
|
|
20
|
Sato A and Asano T, Ito K and Asano T:
Vorinostat and bortezomib synergistically cause ubiquitinated
protein accumulation in prostate cancer cells. J Urol.
188:2410–2418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ocean AJ, Christos P, Sparano JA, Shah MA,
Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman
F, et al: Phase II trial of bortezomib alone or in combination with
irinotecan in patients with adenocarcinoma of the gastroesophageal
junction or stomach. Invest New Drugs. 32:542–548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kozuch PS, Rocha-Lima CM, Dragovich T,
Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP and Lenz HJ:
Bortezomib with or without irinotecan in relapsed or refractory
colorectal cancer: Results from a randomized phase II study. J Clin
Oncol. 26:2320–2326. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Horton TM, Perentesis JP, Gamis AS, Alonzo
TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins
G, et al: A Phase 2 study of bortezomib combined with either
idarubicin/cytarabine or cytarabine/etoposidee in children with
relapsed, refractory or secondary acute myeloid leukemia: A report
from the Children's Oncology Group. Pediatr Blood Cancer.
61:1754–1760. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Petitprez A, Poindessous V, Ouaret D,
Regairaz M, Bastian G, Guérin E, Escargueil AE and Larsen A:
Acquired irinotecan resistance is accompanied by stable
modifications of cell cycle dynamics independent of MSI status. Int
J Oncol. 42:1644–1653. 2013.PubMed/NCBI
|
|
25
|
Groh T, Hrabeta J, Khalil MA, Doktorova H,
Eckschlager T and Stiborova M: The synergistic effects of
DNA-damaging drugs cisplatin and etoposide with a histone
deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Int J Oncol. 47:343–352. 2015.PubMed/NCBI
|
